Literature DB >> 32572775

Antidepressant-Like Effects of Chaihu Shugan Powder () on Rats Exposed to Chronic Unpredictable Mild Stress through Inhibition of Endoplasmic Reticulum Stress-Induced Apoptosis.

Ke-Huan Sun1, Yu Jin1, Zhi-Gang Mei2, Zhi-Tao Feng2, Jie-Ren Liu1, Mei-Qun Cao1, Zheng-Zhi Wu3.   

Abstract

OBJECTIVE: To investigate the antidepressant-like effects of Chaihu Shugan Powder (CSP, ) and to explore its underlying mechanisms.
METHODS: Thirty-two Sprague-Dawley rats were randomly divided into control (CON), chronic unpredictable mild stress (CUMS), fluoxetine (FLU), and CSP groups, 8 rats in each group. All of the rats except for those in the control group were subjected to 3 consecutive weeks of CUMS to establish the depression model. The open field test (OFT), forced swimming test (FST), and sucrose preference test were used to assess the anti-anxiety and antidepressant effects of CSP. Terminal deoxynucleotidyl transferase (TdT) dUTP nick-end labeling was used to determine the apoptosis rate in the hippocampal tissues. The mRNA and protein levels of glucose-regulated protein (GRP) 78, spliced X-box-binding protein (XBP)-1, CCAAT/enhancer-binding protein homologous protein (CHOP), caspase-12, and c-Jun N-terminal kinase (JNK) in the hippocampus of rats were evaluated by real-time PCR and Western blot analysis, respectively.
RESULTS: Administration of CSP alleviated anxiety and depression-like behavior in CUMS rats, as revealed by enhanced time and distance in the center of the OFT (P<0.05), an increased preference for sucrose, and longer swimming time and shorter immobility time during the FST (all P<0.05). In addition, CSP treatment significantly reduced the rate of apoptosis in rat hippocampal neurons (P<0.05). The mRNA and protein expression levels of GRP78, spliced XBP-1, and CHOP were down-regulated along with the expression of caspase-12 and cleaved caspase-12 proteins (all P<0.05), whereas total and phosphorylated JNK1 protein levels did not differ significantly between control and CSP-treated rats.
CONCLUSION: CSP can improve depression-like behavior in rats exposed to CUMS, possibly by suppressing CHOP and caspase-12 mediated apoptosis in the rat hippocampus.

Entities:  

Keywords:  Chaihu Shugan Powder; Chinese medicine; apoptosis; chronic unpredictable mild stress; depression; endoplasmic reticulum stress

Year:  2020        PMID: 32572775     DOI: 10.1007/s11655-020-3228-y

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  2 in total

1.  Behavioral despair in mice: a primary screening test for antidepressants.

Authors:  R D Porsolt; A Bertin; M Jalfre
Journal:  Arch Int Pharmacodyn Ther       Date:  1977-10

Review 2.  The Role of Neural Plasticity in Depression: From Hippocampus to Prefrontal Cortex.

Authors:  Wei Liu; Tongtong Ge; Yashu Leng; Zhenxiang Pan; Jie Fan; Wei Yang; Ranji Cui
Journal:  Neural Plast       Date:  2017-01-26       Impact factor: 3.599

  2 in total
  4 in total

Review 1.  Chinese Herbal Medicine in the Treatment of Depression in Parkinson's Disease: From Molecules to Systems.

Authors:  Yi Zhang; Xiaoman Xu
Journal:  Front Pharmacol       Date:  2022-04-13       Impact factor: 5.988

2.  SIRT1/FOXO1 Axis-Mediated Hippocampal Angiogenesis is Involved in the Antidepressant Effect of Chaihu Shugan San.

Authors:  Shan Zhang; Yujia Lu; Wei Shi; Yi Ren; Kaihui Xiao; Wei Chen; Li Li; Jingjie Zhao
Journal:  Drug Des Devel Ther       Date:  2022-08-23       Impact factor: 4.319

3.  Tao-Hong-Si-Wu decoction improves depressive symptoms in model rats via amelioration of BDNF-CREB-arginase I axis disorders.

Authors:  Xiaoping Zhang; Zeng Li; Chuanpu Shen; Jinzhi He; Longfei Wang; Lei Di; Bin Rui; Ning Li; Zhicheng Liu
Journal:  Pharm Biol       Date:  2022-12       Impact factor: 3.889

4.  Network Pharmacology and Experimental Evidence: PI3K/AKT Signaling Pathway is Involved in the Antidepressive Roles of Chaihu Shugan San.

Authors:  Shan Zhang; Yujia Lu; Wei Chen; Wei Shi; Qian Zhao; Jingjie Zhao; Li Li
Journal:  Drug Des Devel Ther       Date:  2021-08-05       Impact factor: 4.162

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.